12:00 AM
 | 
Oct 01, 2012
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Mundipharma, SkyePharma sales and marketing update

SkyePharma said the Napp Pharmaceuticals Ltd. affiliate of Mundipharma launched flutiform fluticasone/formoterol in the U.K. to treat asthma. The launch triggers a £4 million ($6.5 million) payment to SkyePharma. The National Health Service (NHS) prices for the drug will be...

Read the full 187 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >